Clinical trials: High Grade Endometrioid Ovarian Cancer
To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer
BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer
PURPOSE: To investigate the prevalence and clinical correlation of the germline BRCA 1/2 mutation in Korean patients with high grade(HG) serous and/or endometrioid epithelial ovarian cancer (EOC).
- Trial name
- NCT02963688
- Testing
- Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform
- Volunteers
- 298 people
- Sponsor
- Samsung Medical Center
Ovarian Cancer, Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL3 (NCT01968213)
- Testing
- Rucaparib
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 564 people
- Sponsor
- pharmaand GmbH
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and berzosertib when given together with carboplatin in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has…
- Conditions
- Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor
- Trial name
- NCT02627443
- Testing
- Berzosertib, Carboplatin, Gemcitabine Hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer Recurrent
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly.
- Trial name
- NCT06843447
- Testing
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel
- Where
- 39 sites in United States, Canada and 6 more
- Volunteers
- 605 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a…
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
- Trial name
- NCT04092270
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 11 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial…
- Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT07504588
- Testing
- Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014
- Trial name
- NCT06580314
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 695 sites in United States, Japan and 1 more
- Volunteers
- 880 people
- Sponsor
- NRG Oncology
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not…
- Conditions
- Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT03924245
- Testing
- Entinostat, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs.
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
- Trial name
- NCT04739800
- Testing
- Biospecimen Collection, Cediranib Maleate, Computed Tomography
- Where
- 391 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Ovarian Carcinoma
Study of NTB-928 in R/R OC
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the…
- Trial name
- NCT07690189
- Testing
- NTB-928
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- TeneoSeven, Inc.
Peritoneal Carcinomatosis, Ovarian Cancer
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade…
- Trial name
- NCT06504147
- Testing
- Radspherin
- Where
- 10 sites in United States, Belgium and 4 more
- Volunteers
- 114 people
- Sponsor
- Oncoinvent Solutions AS
Fallopian Tube Cancer
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer
To maximise the accessibility and benefit of PARP inhibitors to eligible patients, it is essential to know the prevalence of HRD in women with advanced high-grade serous or endometrioid ovarian cancer.
- Trial name
- HALO (NCT04991051)
- Where
- 24 sites in Kuwait, Oman and 4 more
- Volunteers
- 605 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Relapsed Ovarian Cancer
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a…
- Conditions
- Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ACTOv (NCT05080556)
- Testing
- Carboplatin
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH
Ovarian Cancer, Fallopian Tube Cancer
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
This is a phase II study in patients with recurrent platinum resistant or refractory C5 high-grade serous, endometrioid or undifferentiated ovarian, primary peritoneal or fallopian tube cancer.
- Trial name
- NCT03188159
- Testing
- Vinorelbine
- Where
- 2 sites in Australia, Singapore
- Volunteers
- 36 people
- Sponsor
- National University Hospital, Singapore
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent).
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma
- Trial name
- NCT02345265
- Testing
- Biopsy Procedure, Biospecimen Collection, Cediranib Maleate
- Where
- 20 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian…
- Conditions
- Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)
- Trial name
- MATAO (NCT04111978)
- Testing
- Letrozole 2.5mg
- Where
- 53 sites in Austria, Germany and 1 more
- Volunteers
- 540 people
- Sponsor
- Swiss GO Trial Group
Ovarian Cancer, Peritoneal Cancer
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07743164
- Testing
- R-DXd, Bevacizumab, Carboplatin
- Where
- 4 sites in United States, Israel and 1 more
- Volunteers
- 646 people
- Sponsor
- Merck Sharp & Dohme LLC